GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Short-Term Capital Lease Obligation

Accelerated Pharma (Accelerated Pharma) Short-Term Capital Lease Obligation : $0.00 Mil (As of Mar. 2017)


View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Short-Term Capital Lease Obligation?

Accelerated Pharma's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2017 was $0.00 Mil.


Accelerated Pharma Short-Term Capital Lease Obligation Historical Data

The historical data trend for Accelerated Pharma's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Short-Term Capital Lease Obligation Chart

Accelerated Pharma Annual Data
Trend Dec14 Dec15 Dec16
Short-Term Capital Lease Obligation
- - -

Accelerated Pharma Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Short-Term Capital Lease Obligation Get a 7-Day Free Trial - - - - -

Accelerated Pharma Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.


Accelerated Pharma Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Accelerated Pharma (Accelerated Pharma) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Website
Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines